Pleural Effusion clinical trials at UCSD
1 research study open to eligible people
open to eligible people ages 18 years and up
The LTI-01-2001 study is a double-blind, placebo-controlled, Phase 2 study to evaluate LTI-01 (single-chain urokinase plasminogen activator, scuPA) in patients with infected, non-draining pleural effusions.
La Jolla, California and other locations
Our lead scientists for Pleural Effusion research studies include George Cheng, MD.